Risk factors for post-transplant lymphoproliferative disease in patients with cystic fibrosis

Saueressig MG, Boussaud V, Amrein C, Guillemain R, Souilamas J, Souilamas R. Risk factors for post‐transplant lymphoproliferative disease in patients with cystic fibrosis. Clin Transplant 2011: 25: E430–E436. © 2011 John Wiley & Sons A/S. : The objective of this study was to retrospectively analyze risk factors associated with post‐transplant lymphoproliferative disease (PTLD) in a cohort of 112 lung transplant recipients with cystic fibrosis (CF). Prior to transplantation, patients were tested for Epstein–Barr virus (EBV), human herpesvirus (HHV types 1, 2, 3, 6, and 8), herpes zoster virus, and cytomegalovirus (CMV) serologies. PTLD diagnosis was established based on increased EBV viral charge plus clinical/radiographic findings and confirmed by biopsy. Negative EBV and HHV serologies at the time of lung transplantation (LTx) were significant risk factors associated with development of PTLD in patients with CF in the univariate logistic regression analysis (p